1. Hydroxychloroquine use in hospitalized and tocilizumab use in ICU lab-positive COVID-19 patients were not been associated with decreased death. ...
1. Hydroxychloroquine use in hospitalized and tocilizumab use in ICU lab-positive COVID-19 patients were not been associated with decreased death. ...
1. Prophylactic use of hydroxychloroquine within four days after exposure did not decrease cumulative incidence of coronavirus disease 2019 (Covid-19). ...
1. Metformin was found to be safe and tolerable in survivors of pediatric brain tumors. 2. Metformin was associated with ...
1. Prophylactic use of hydroxychloroquine within four days after exposure did not decrease cumulative incidence of coronavirus disease 2019 (Covid-19). ...
1. Hydroxychloroquine use with or without azithromycin did not improve clinical outcomes at fifteen days when compared with standard of ...
1. In this double-blind, randomized trial, hydroxychloroquine did not reduce symptom severity in an adult, outpatient population. 2. More side ...
1. In this double-blind, randomized trial, hydroxychloroquine did not reduce symptom severity in an adult, outpatient population. 2. More side ...
1. Hydroxychloroquine use as post-exposure prophylaxis within 4 days of a moderate or high-risk exposure did not prevent illness compatible ...
1. Use of hydroxychloroquine with or without azithromycin to treat COVID-19 was frequently associated with QTc prolongation, with results being ...
